COVID-KOSHA
Home
Help
(current)
Comment
!
Note: Language translations may be imperfect
A model anti-pandemic portal for scientists & public
;
High priority articles (R1, Most articles most likely to be relevant):
Second priority articles (R2, Moderate portion of articles likely to be relevant):
Other articles (R3, Lesser portion of articles likely to be relevant):
Articles Not Curated -
Drug studies in humans
Last updated: 2025 May 18
Total hit(s): 8159
S.No.
PMID
Ascending order
Descending order
Title
Ascending order
Descending order
Journal Name
Ascending order
Descending order
Publish Date
Ascending order
Descending order
Impact Factor
Ascending order
Descending order
Citations
Ascending order
Descending order
1
40214651
From Wuhan to Omicron K.P2 strain: A comprehensive review of SARS-CoV-2 phylogeny and public health implications of the latest booster vaccine.
Hum Vaccin Immunother
2025 Dec
4.7
1
2
40195167
Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a pooled phase 1/2/3 randomized clinical study.
Expert Rev Vaccines
2025 Dec
4.37
1
3
40051347
Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection.
Hum Vaccin Immunother
2025 Dec
4.7
1
4
40329514
Integrating immune library probing with structure-based computational design to develop potent neutralizing nanobodies against emerging SARS-CoV-2 variants.
MAbs
2025 Dec
10
1
5
39887328
Willingness to pay for the effect of SARS-CoV-2 antivirals in preventing COVID-19 transmission to others in the Japanese population.
J Med Econ
2025 Dec
1
6
40371698
Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity.
J Enzyme Inhib Med Chem
2025 Dec
8.6
1
7
40366666
A four-week study on the toxicity of repeated intramuscular administration of plant-based BA-CoV2-0301 vaccine against SARS-CoV-2 in Sprague-Dawley rats.
J Immunotoxicol
2025 Dec
1
8
40028815
Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models.
Hum Vaccin Immunother
2025 Dec
4.7
1
9
40381203
Safety and immunogenicity of SARS-CoV-2 protein subunit recombinant vaccine (Indovac(R)) in healthy populations aged 18 years and above in Indonesia: A phase I, observer-blind, randomized, controlled study.
Hum Vaccin Immunother
2025 Dec
4.7
1
10
40214201
A One Health approach to bovine coronavirus vaccine development, using LSDV as a live virus vector.
Hum Vaccin Immunother
2025 Dec
4.7
1
11
40432512
Neutralizing antibody levels as a key factor in determining the immunogenic efficacy of the novel PEDV alpha coronavirus vaccine.
Vet Q
2025 Dec
8.5
1
12
40376714
Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial.
Hum Vaccin Immunother
2025 Dec
4.7
1
13
40134119
Gaps in vaccine clinical trials in Africa: A mixed scoping review and bibliometric analysis before, during, and post- COVID-19 pandemic.
Hum Vaccin Immunother
2025 Dec
4.7
1
14
39834144
Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants.
Expert Rev Vaccines
2025 Dec
4.37
1
15
39865693
Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial.
Hum Vaccin Immunother
2025 Dec
4.7
1
16
40077853
Characterization of the binding features between SARS-CoV-2 5'-proximal transcripts of genomic RNA and nucleocapsid proteins.
RNA Biol
2025 Dec
1
17
40045463
The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants.
Hum Vaccin Immunother
2025 Dec
4.7
1
18
39643949
Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia.
Expert Rev Vaccines
2025 Dec
4.37
1
19
39720838
Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged >/=18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial.
Expert Rev Vaccines
2025 Dec
4.37
1
20
40288233
Evaluation of SARS-CoV-2 antibody detection methods for wild Cervidae.
Prev Vet Med
2025 Aug
2.33
1
21
40440921
Risk of Guillain-Barre syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
Vaccine
2025 Jul 11
3.31
1
22
40510179
The effect of dual inflammation on the acute phase clinical outcomes of schizophrenia patients with comorbid COVID-19.
Brain Behav Immun Health
2025 Jul
1
23
40419190
Successive SARS-CoV-2 mutations in a highly susceptible host: A case report of persistent viremia and fatality.
J Infect Chemother
2025 Jul
1.59
1
24
40436249
A nationwide epidemiological survey of coronavirus disease 2019-associated pulmonary aspergillosis in Japan.
J Infect Chemother
2025 Jul
1.59
1
25
40522253
Analysis of Hyperexpanded T Cell Clones in SARS-CoV-2 Vaccine-Associated Liver Injury by Spatial Proteomics and Transcriptomics.
Liver Int
2025 Jul
5.2
1